vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Lanvin Group Holdings Ltd (LANV). Click either name above to swap in a different company.
Lanvin Group Holdings Ltd is the larger business by last-quarter revenue ($144.1M vs $83.5M, roughly 1.7× BillionToOne, Inc.).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Lanvin is a French luxury fashion house founded in 1889 by Jeanne Lanvin in Paris. It is the oldest French fashion house still in operation. Since 2018, it has been a subsidiary of Shanghai-based Lanvin Group. Lanvin Group includes Lanvin, Sergio Rossi, Wolford, St. John Knits, and Caruso.
BLLN vs LANV — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $144.1M |
| Net Profit | $5.7M | — |
| Gross Margin | 69.9% | 53.9% |
| Operating Margin | 11.5% | -60.5% |
| Net Margin | 6.8% | — |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $83.5M | — | ||
| Q2 25 | — | $144.1M | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | — | $184.7M | ||
| Q2 23 | — | $231.7M |
| Q3 25 | $5.7M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $-14.9M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | 53.9% | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | 57.5% | ||
| Q2 23 | — | 58.5% |
| Q3 25 | 11.5% | — | ||
| Q2 25 | — | -60.5% | ||
| Q3 24 | -32.9% | — | ||
| Q2 24 | — | -35.0% | ||
| Q2 23 | — | -32.5% |
| Q3 25 | 6.8% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | -38.8% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | $0.10 | — | ||
| Q2 25 | — | — | ||
| Q3 24 | $-1.47 | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $32.1M |
| Total DebtLower is stronger | $55.0M | $290.3M |
| Stockholders' EquityBook value | $-239.5M | $-116.4M |
| Total Assets | $327.5M | $632.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $195.2M | — | ||
| Q2 25 | — | $32.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $19.3M | ||
| Q2 23 | — | — |
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | $290.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $136.4M | ||
| Q2 23 | — | — |
| Q3 25 | $-239.5M | — | ||
| Q2 25 | — | $-116.4M | ||
| Q3 24 | $-242.9M | — | ||
| Q2 24 | — | $100.1M | ||
| Q2 23 | — | — |
| Q3 25 | $327.5M | — | ||
| Q2 25 | — | $632.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $731.8M | ||
| Q2 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.36× | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-75.1K |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $13.8M | — | ||
| Q2 25 | — | $-75.1K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-36.2K | ||
| Q2 23 | — | $-62.8K |
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
LANV
Segment breakdown not available.
